AAM
MRVI icon

Azzad Asset Management’s Maravai LifeSciences MRVI Stock Holding History

Azzad Asset Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-19,671
Closed -$701K – 332
2021
Q1 		$701K Buy
+19,671
New +$652K 0.12% 248

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Azzad Asset Management's MRVI Position: Q2 2021 in Review

Azzad Asset Management sold out of Maravai LifeSciences (MRVI) in Q2 2021, closing a stake of 19,671 shares — an estimated $701K sold.

Azzad Asset Management first reported a position in MRVI in Q1 2021 and held it in 1 quarter. The position peaked at $701K in Q1 2021. 196 funds tracked by Wall St. Rank hold MRVI as of Q2 2021.

  • Azzad Asset Management reported no remaining Maravai LifeSciences position as of Q2 2021 after selling out during the quarter.
  • Azzad Asset Management sold 19,671 Maravai LifeSciences shares in Q2 2021, an estimated $701K.
  • Azzad Asset Management first reported a position in Maravai LifeSciences in Q1 2021 and held it in 1 quarter.
  • Azzad Asset Management's Maravai LifeSciences position peaked at $701K in Q1 2021.
  • 196 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2021.

Based on Azzad Asset Management's 13F filing for Q2 2021, filed 1 Apr 2024.